title: Increased circulating soluble P-selectin in polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine whether the P-selectin-von Willebrand factor (vWF) pathway is altered in patients with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Case-control study.
  
  
  METHODS
  Tertiary care academic medical center.
  
  
  METHODS
  Thirty-two normal glucose-tolerant patients with PCOS and 21 age- and body mass index-matched healthy women were prospectively enrolled. All the patients with PCOS had clinical and/or biochemical hyperandrogenism and chronic oligoanovulation, and 89% had polycystic ovaries on ultrasound.
  
  
  METHODS
  None.
  
  
  METHODS
  Soluble P-selectin (sP-selectin), vWF, total T, sex hormone-binding globulin, total cholesterol, high-density lipoprotein cholesterol, triglycerides, fasting glucose and insulin, 2-hour glucose, and homeostatic model assessment-insulin resistance.
  
  
  RESULTS
  Soluble P-selectin levels were significantly higher in patients with PCOS compared with controls (58.7 +/- 19.0 vs. 45.3 +/- 15.0 ng/mL), whereas PCOS and control groups had similar vWF levels (46.7 +/- 24.2 vs. 39.5 +/- 22.3, respectively). There was no correlation between sP-selectin and anthropometric measurements or any of the androgen, lipid, or insulin resistance parameters.
  
  
  CONCLUSIONS
  Our results suggest increments in the circulating sP-selectin concentrations associated with unaltered vWF levels in PCOS. Increased sP-selectin might potentially contribute to the future risk of cardiovascular disease in patients with PCOS.
authors.affiliation: Endocrinology and Metabolism Unit, Department of Internal Medicine, Hacettepe University School of Medicine, Hacettepe, Ankara 06100, Turkey. yildizbo@yahoo.com
authors.forename: Bulent O
authors.initials: BO
authors.lastname: Yildiz
authors.forename: Gurkan
authors.initials: G
authors.lastname: Bozdag
authors.forename: Ayla
authors.initials: A
authors.lastname: Harmanci
authors.forename: Umit
authors.initials: U
authors.lastname: Otegen
authors.forename: Kubra
authors.initials: K
authors.lastname: Boynukalin
authors.forename: Zehra
authors.initials: Z
authors.lastname: Vural
authors.forename: Serafettin
authors.initials: S
authors.lastname: Kirazli
authors.forename: Ibrahim C
authors.initials: IC
authors.lastname: Haznedaroglu
authors.forename: Hakan
authors.initials: H
authors.lastname: Yarali
mesh_terms: D000328:Adult; D015992:Body Mass Index; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000097:blood; D019007:P-Selectin / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood*; D012995:Solubility; D015854:Up-Regulation; D055105:Waist Circumference; D055815:Young Adult; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D007328:Insulin; D008055:Lipids; D019007:P-Selectin; D014841:von Willebrand Factor